NASDAQ:SCLX Scilex Q1 2026 Earnings Report $5.10 -0.25 (-4.67%) Closing price 09/23/2026 04:00 PM EasternExtended Trading$5.12 +0.02 (+0.29%) As of 09/23/2026 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Scilex EPS ResultsActual EPS-$4.76Consensus EPS -$0.34Beat/MissMissed by -$4.42One Year Ago EPSN/AScilex Revenue ResultsActual Revenue$8.61 millionExpected Revenue$15.00 millionBeat/MissMissed by -$6.39 millionYoY Revenue GrowthN/AScilex Announcement DetailsQuarterQ1 2026Date5/20/2026TimeBefore Market OpensConference Call DateWednesday, May 20, 2026Conference Call Time8:00AM ETUpcoming EarningsScilex's Q3 2026 earnings is estimated for Wednesday, December 2, 2026, based on past reporting schedulesConference Call ResourcesQuarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsQuarterly report(10-Q) Scilex Earnings HeadlinesScilex Establishes $20 Million Credit Facility for VivasorAugust 12, 2026 | tipranks.comScilex Announces Strategic Sale of Vivasor Preferred SharesJuly 22, 2026 | tipranks.comNASA's ISS Replacement Could Go to This Tiny Space FirmNASA has commissioned SpaceX to decommission the $150 billion International Space Station, but the contract to build its replacement is reportedly headed to a tiny firm a fraction of SpaceX's size, one NASA has quietly funded for five years. History shows these NASA announcements can move fast: Intuitive Machines jumped 66% in a day, Momentus soared 155%, and Sidus Space climbed 180% after landing subcontractor roles.September 24 at 1:00 AM | Behind the Markets (Ad)Scilex Holding CompanyJuly 16, 2026 | cnn.comSemnur Pharmaceuticals, Inc. (“Semnur”), a Majority-Owned Subsidiary of Scilex Holding Company (Nasdaq: SCLX, “Scilex”), Announces Signing of Binding Term Sheet for ...July 7, 2026 | finance.yahoo.comSemnur Pharmaceuticals, Inc. (“Semnur”), a Majority-Owned Subsidiary of Scilex Holding Company (Nasdaq: SCLX, “Scilex”), Announces Signing of Binding Term Sheet for Proposed $100 Million Strategic Investment from iHolding Group LLPJuly 7, 2026 | globenewswire.comSee More Scilex Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Scilex? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Scilex and other key companies, straight to your email. Email Address About ScilexScilex (NASDAQ:SCLX) is a commercial-stage pharmaceutical company focused on developing and commercializing non-opioid treatments for acute and chronic pain. The company’s portfolio includes prescription products intended to address conditions such as neuropathic pain, migraine and gout-related pain and inflammation. Scilex markets ZTlido, a prescription topical lidocaine system approved for the relief of pain associated with postherpetic neuralgia. Its portfolio also includes ELYXYB, an oral solution of celecoxib approved for the acute treatment of migraine with or without aura in adults, and GLOPERBA, an oral liquid colchicine product indicated for the treatment and prevention of gout flares in adults. The company has also pursued additional investigational pain therapies, including product candidates designed for localized and non-opioid pain relief. Scilex primarily serves the United States through prescription pharmaceutical channels and commercial partnerships. Jaisim Shah has served as the company’s chief executive officer and president. Scilex was established as a specialty pharmaceutical business and became a publicly traded company through a business combination in 2022.View Scilex ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Energy Transfer Taps the AI Power BoomFull Throttle: Kratos and GE Fire Up a Next-Gen Defense EngineSandisk Joins the S&P 100—Is the Index Flow, or the AI Story, Driving the Stock?Thor Industries Is Boring—And That May Be Its Biggest AdvantageAutoZone Shifts Gears, On Track to Reverse Course and Price RecoveryMeta’s Muse Highlights Arm’s Growing Role in AI InfrastructureOld Dogs, New Tech: 3 Legacy Stocks Powering the AI Boom Upcoming Earnings Micron Technology (9/30/2026)NIKE (10/1/2026)Accenture (10/1/2026)PepsiCo (10/8/2026)Delta Air Lines (10/9/2026)America Movil (10/13/2026)BlackRock (10/13/2026)Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
